Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force

被引：31

作者：

Lee, Ho ^{[1
]}

Chubachi, Shotaro ^{[1
]}

Namkoong, Ho ^{[2
]}

Asakura, Takanori ^{[1
]}

Tanaka, Hiromu ^{[1
]}

Otake, Shiro ^{[1
]}

Nakagawara, Kensuke ^{[1
]}

Morita, Atsuho ^{[1
]}

Fukushima, Takahiro ^{[1
]}

Watase, Mayuko ^{[1
]}

Kusumoto, Tatsuya ^{[1
]}

Masaki, Katsunori ^{[1
]}

Kamata, Hirofumi ^{[1
]}

Ishii, Makoto ^{[1
]}

Hasegawa, Naoki ^{[3
,4
]}

Harada, Norihiro

Ueda, Tetsuya ^{[5
]}

Ueda, Soichiro ^{[6
]}

Ishiguro, Takashi ^{[7
]}

Arimura, Ken ^{[8
]}

Saito, Fukuki ^{[9
]}

Yoshiyama, Takashi ^{[10
]}

Nakano, Yasushi ^{[11
]}

Mutoh, Yoshikazu ^{[12
]}

Suzuki, Yusuke ^{[13
]}

Murakami, Koji ^{[14
]}

Okada, Yukinori ^{[15
,16
,17
]}

Koike, Ryuji ^{[18
]}

Kitagawa, Yuko ^{[19
]}

Kimura, Akinori ^{[20
]}

Imoto, Seiya

Miyano, Satoru ^{[22
]}

Ogawa, Seishi ^{[21
,23
]}

Kanai, Takanori

Fukunaga, Koichi ^{[1
]}

机构：

[1] Keio Univ, Sch Med, Dept Med, Div Pulm Med, 35 Shinanomachi,Shinjuku Ku, Tokyo 1608582, Japan

[2] Keio Univ, Sch Med, Dept Infect Dis, 35 Shinanomachi,Shinjuku Ku, Tokyo 1608582, Japan

[3] Juntendo Univ, Fac Med, Dept Resp Med, Tokyo, Japan

[4] Grad Sch Med, Tokyo, Japan

[5] Osaka Saiseikai Nakatsu Hosp, Dept Resp Med, Osaka, Japan

[6] JCHO Japan Community Hlth Care Org, Saitama Med Ctr, Internal Med, Saitama, Japan

[7] Saitama Cardiovasc & Resp Ctr, Dept Resp Med, Kumagaya, Japan

[8] Tokyo Womens Med Univ, Dept Resp Med, Tokyo, Japan

[9] Kansai Med Univ Gen Med Ctr, Dept Emergency & Crit Care Med, Moriguchi, Japan

[10] Fukujuji Hosp, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Kiyose, Japan

[11] Kawasaki Municipal Ida Hosp, Dept Internal Med, Kawasaki, Japan

[12] Tosei Gen Hosp, Dept Infect Dis, Seto, Japan

[13] Kitasato Univ, Dept Resp Med, Kitasato Inst Hosp, Tokyo, Japan

[14] Tohoku Univ, Dept Resp Med, Grad Sch Med, Sendai, Japan

[15] Osaka Univ, Dept Stat Genet, Grad Sch Med, Suita, Japan

[16] RIKEN Ctr Integrat Med Sci, Lab Syst Genet, Yokohama, Kanagawa, Japan

[17] Univ Tokyo, Grad Sch Med, Dept Genome Informat, Tokyo, Japan

[18] Tokyo Med & Dent Univ, Med Innovat Promot Ctr, Tokyo, Japan

[19] Keio Univ, Dept Surg, Sch Med, Tokyo, Japan

[20] Tokyo Med & Dent Univ, Inst Res, Tokyo, Japan

[21] Univ Tokyo, Inst Med Sci, Human Genome Ctr, Div Hlth Med Intelligence, Tokyo, Japan

[22] Tokyo Med & Dent Univ, M&D Data Sci Ctr, Tokyo, Japan

[23] Kyoto Univ, Dept Pathol & Tumor Biol, Kyoto, Japan

来源：

BMC INFECTIOUS DISEASES | 2022年 / 22卷 / 01期

关键词：

COVID-19; Wave of infection; Respiratory infection; Hospitalization; PNEUMONIA; DISEASE; OSAKA;

D O I：

10.1186/s12879-022-07927-w

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

BackgroundWe aimed to elucidate differences in the characteristics of patients with coronavirus disease 2019 (COVID-19) requiring hospitalization in Japan, by COVID-19 waves, from conventional strains to the Delta variant. MethodsWe used secondary data from a database and performed a retrospective cohort study that included 3261 patients aged >= 18 years enrolled from 78 hospitals that participated in the Japan COVID-19 Task Force between February 2020 and September 2021. ResultsPatients hospitalized during the second (mean age, 53.2 years [standard deviation {SD}, +/- 18.9]) and fifth (mean age, 50.7 years [SD & PLUSMN; 13.9]) COVID-19 waves had a lower mean age than those hospitalized during the other COVID-19 waves. Patients hospitalized during the first COVID-19 wave had a longer hospital stay (mean, 30.3 days [SD & PLUSMN; 21.5], p < 0.0001), and post-hospitalization complications, such as bacterial infections (21.3%, p < 0.0001), were also noticeable. In addition, there was an increase in the use of drugs such as remdesivir/baricitinib/tocilizumab/steroids during the latter COVID-19 waves. In the fifth COVID-19 wave, patients exhibited a greater number of presenting symptoms, and a higher percentage of patients required oxygen therapy at the time of admission. However, the percentage of patients requiring invasive mechanical ventilation was the highest in the first COVID-19 wave and the mortality rate was the highest in the third COVID-19 wave. ConclusionsWe identified differences in clinical characteristics of hospitalized patients with COVID-19 in each COVID-19 wave up to the fifth COVID-19 wave in Japan. The fifth COVID-19 wave was associated with greater disease severity on admission, the third COVID-19 wave had the highest mortality rate, and the first COVID-19 wave had the highest percentage of patients requiring mechanical ventilation.

引用

页数：15

共 45 条

[1]

[Anonymous], 2021, LANCET, V397, P1683, DOI 10.1016/S0140-6736(21)01052-7

[2]

[Anonymous], Vaccination schedule for The Gambia

[3]

[Anonymous], RECOMMENDATIONS AVOI

[4]

[Anonymous], Our World in Data: Coronavirus (COVID-19) Vaccinations

[5]

[Anonymous], CLIN MANAGEMENT PATI

[6] COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow [J].

Bikdeli, Behnood ;

Madhavan, Mahesh V. ;

Jimenez, David ;

Chuich, Taylor ;

Dreyfus, Isaac ;

Driggin, Elissa ;

Der Nigoghossian, Caroline ;

Ageno, Walter ;

Madjid, Mohammad ;

Guo, Yutao ;

Tang, Liang V. ;

Hu, Yu ;

Giri, Jay ;

Cushman, Mary ;

Quere, Isabelle ;

Dimakakos, Evangelos P. ;

Gibson, C. Michael ;

Lippi, Giuseppe ;

Favaloro, Emmanuel J. ;

Fareed, Jawed ;

Caprini, Joseph A. ;

Tafur, Alfonso J. ;

Burton, John R. ;

Francese, Dominic P. ;

Wang, Elizabeth Y. ;

Falanga, Anna ;

McLintock, Claire ;

Hunt, Beverley J. ;

Spyropoulos, Alex C. ;

Barnes, Geoffrey D. ;

Eikelboom, John W. ;

Weinberg, Ido ;

Schulman, Sam ;

Carrier, Marc ;

Piazza, Gregory ;

Beckman, Joshua A. ;

Steg, Gabriel ;

Stone, Gregg W. ;

Rosenkranz, Stephan ;

Goldhaber, Samuel Z. ;

Parikh, Sahil A. ;

Monreal, Manuel ;

Krumholz, Harlan M. ;

Konstantinides, Stavros V. ;

Weitz, Jeffrey I. ;

Lip, Gregory Y. H. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (23) :2950-2973

[7] RETRACTED: Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study (Retracted Article) [J].

Cai, Qingxian ;

Yang, Minghui ;

Liu, Dongjing ;

Chen, Jun ;

Shu, Dan ;

Xia, Junxia ;

Liao, Xuejiao ;

Gu, Yuanbo ;

Cai, Qiue ;

Yang, Yang ;

Shen, Chenguang ;

Li, Xiaohe ;

Peng, Ling ;

Huang, Deliang ;

Zhang, Jing ;

Zhang, Shurong ;

Wang, Fuxiang ;

Liu, Jiaye ;

Chen, Li ;

Chen, Shuyan ;

Wang, Zhaoqin ;

Zhang, Zheng ;

Cao, Ruiyuan ;

Zhong, Wu ;

Liu, Yingxia ;

Liu, Lei .

ENGINEERING, 2020, 6 (10) :1192-1198

[8]

Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]

[9] Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study [J].

Challen, Robert ;

Brooks-Pollock, Ellen ;

Read, Jonathan M. ;

Dyson, Louise ;

Tsaneva-Atanasova, Krasimira ;

Danon, Leon .

BMJ-BRITISH MEDICAL JOURNAL, 2021, 372

[10] Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials [J].

Chen, Ching-Yi ;

Chen, Wang-Chun ;

Hsu, Chi-Kuei ;

Chao, Chien-Ming ;

Lai, Chih-Cheng .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 99

← 1 2 3 4 5 →